Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics, Inc. expected to post a loss of 14 cents a share - Earnings Preview
TradingView · 23 Oct 2026
Kaplan Fox is Investigating Whether Fulcrum Therapeutics, Inc. (N
The National Law Review · 09 Oct 2026
A roughly 5% fully diluted stake and a pre-merger cash dividend are expected for Fulcrum (FULC) holders.
Stock Titan · 08 Oct 2026

Headlines from the last 30 days, linking to the original publishers. See all market news →

Disclaimer — PositoAI is a research and screening tool for educational and informational purposes. It is not investment advice or a recommendation to buy or sell any security or mutual fund. Scores and rankings are calculated by PositoAI's own method using publicly available data, which may be incomplete, delayed or inaccurate, and past performance does not indicate future results. AI summaries of company news may contain errors. PositoAI is not registered with the SEC, SEBI or any other regulatory authority. Please do your own research or consult a licensed financial advisor before investing.